- Home
- CDNA vs BELFB Comparison
CDNA vs BELFB Comparison
Compare CDNA & BELFB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- BELFB
- Stock Information
- Founded
- CDNA 1998
- BELFB 1949
- Country
- CDNA United States
- BELFB United States
- Employees
- CDNA N/A
- BELFB N/A
- Industry
- CDNA Medical Specialities
- BELFB
- Sector
- CDNA Health Care
- BELFB
- Exchange
- CDNA Nasdaq
- BELFB Nasdaq
- Market Cap
- CDNA 1.0B
- BELFB 865.9M
- IPO Year
- CDNA 2014
- BELFB N/A
- Fundamental
- Price
- CDNA $19.04
- BELFB $90.51
- Analyst Decision
- CDNA Buy
- BELFB Strong Buy
- Analyst Count
- CDNA 6
- BELFB 4
- Target Price
- CDNA $30.33
- BELFB $95.75
- AVG Volume (30 Days)
- CDNA 996.2K
- BELFB 134.5K
- Earning Date
- CDNA 07-30-2025
- BELFB 07-23-2025
- Dividend Yield
- CDNA N/A
- BELFB 0.31%
- EPS Growth
- CDNA N/A
- BELFB N/A
- EPS
- CDNA 1.07
- BELFB 3.42
- Revenue
- CDNA $346,421,000.00
- BELFB $558,940,000.00
- Revenue This Year
- CDNA $13.31
- BELFB $18.21
- Revenue Next Year
- CDNA $15.46
- BELFB $7.91
- P/E Ratio
- CDNA $17.61
- BELFB $26.34
- Revenue Growth
- CDNA 25.92
- BELFB N/A
- 52 Week Low
- CDNA $13.48
- BELFB $58.00
- 52 Week High
- CDNA $34.84
- BELFB $92.61
- Technical
- Relative Strength Index (RSI)
- CDNA 55.64
- BELFB 75.49
- Support Level
- CDNA $18.51
- BELFB $85.18
- Resistance Level
- CDNA $19.62
- BELFB $91.61
- Average True Range (ATR)
- CDNA 0.84
- BELFB 3.30
- MACD
- CDNA 0.02
- BELFB 1.35
- Stochastic Oscillator
- CDNA 66.12
- BELFB 94.70
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.